[go: up one dir, main page]

MX2015011576A - Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. - Google Patents

Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos.

Info

Publication number
MX2015011576A
MX2015011576A MX2015011576A MX2015011576A MX2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A
Authority
MX
Mexico
Prior art keywords
thienopyrimidine
methods
compositions
thienopyridine compounds
mll1
Prior art date
Application number
MX2015011576A
Other languages
English (en)
Inventor
Jolanta Grembecka
Thomasz Cierpicki
Dmitry Borkin
Jay Hess
Duxin Sun
Xiaoqin Li
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of MX2015011576A publication Critical patent/MX2015011576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere generalmente a compuestos de clase tienopirimidina y tienopiridina, y sus métodos de uso. En las modalidades particulares, la presente invención proporciona composiciones que comprenden compuestos de clase tienopirimidina y tienopiridina y métodos de uso para inhibir la interacción de menina con oncoproteínas de fusión MLL1, MLL2 y MLL (por ejemplo, para el tratamiento de leucemia, cánceres sólidos y otras enfermedades que dependen de la actividad de las proteínas de fusión de MLL1, MLL2 y MLL y/o menina).
MX2015011576A 2013-03-13 2014-03-10 Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. MX2015011576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2015011576A true MX2015011576A (es) 2016-05-16

Family

ID=51529943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011576A MX2015011576A (es) 2013-03-13 2014-03-10 Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos.

Country Status (11)

Country Link
US (4) US9216993B2 (es)
EP (1) EP2968342B1 (es)
JP (2) JP2016512514A (es)
KR (1) KR20150130389A (es)
CN (1) CN105188705A (es)
AU (1) AU2014249233A1 (es)
BR (1) BR112015022602A2 (es)
CA (1) CA2904612A1 (es)
IL (1) IL241193A0 (es)
MX (1) MX2015011576A (es)
WO (1) WO2014164543A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502301YA (en) * 2012-09-28 2015-04-29 Cancer Rec Tech Ltd Azaquinazoline inhibitors of atypical protein kinase c
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10526341B2 (en) * 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
ES3044036T3 (en) * 2016-01-26 2025-11-26 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
MX387806B (es) * 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
SMT202300273T1 (it) * 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
MX384087B (es) 2016-05-02 2025-03-14 Univ Michigan Regents Piperidinas como inhibidores de menina.
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
PT3468966T (pt) * 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
HUE053907T2 (hu) * 2016-09-14 2021-07-28 Janssen Pharmaceutica Nv A menin-MLL kölcsönhatás spiro-biciklusos inhibitorai
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
CN109715634B (zh) 2016-09-14 2022-09-27 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
AU2017376599B2 (en) * 2016-12-15 2021-10-07 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
CA3058448A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
KR20200101389A (ko) * 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
WO2019189732A1 (ja) * 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状２級アミン誘導体
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020032105A1 (ja) 2018-08-08 2020-02-13 大日本住友製薬株式会社 光学活性な架橋型ピペリジン誘導体
WO2020072391A1 (en) 2018-10-03 2020-04-09 The Regents Of The University Of Michigan Small molecule menin inhibitors
EP3871673B1 (en) 2018-10-26 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel indazole compound or salt thereof
KR102912146B1 (ko) 2018-12-06 2026-01-14 다이이찌 산쿄 가부시키가이샤 시클로알칸-1,3-디아민 유도체
JP7458406B2 (ja) 2018-12-21 2024-03-29 セルジーン コーポレーション Ｒｉｐｋ２のチエノピリジン阻害剤
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
MX2022005053A (es) 2019-10-28 2022-05-18 Merck Sharp & Dohme Llc Inhibidores de peque?as moleculas de mutante g12c de kras.
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
WO2022237626A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
BR112023023463A2 (pt) 2021-05-14 2024-01-30 Syndax Pharmaceuticals Inc Inibidores da interação menin-mll
MX2023014347A (es) 2021-06-01 2023-12-13 Janssen Pharmaceutica Nv Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos.
EP4347600A1 (en) 2021-06-03 2024-04-10 JANSSEN Pharmaceutica NV Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
PE20240923A1 (es) 2021-06-17 2024-04-30 Janssen Pharmaceutica Nv Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil) (metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cancer
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
AU2022424212B2 (en) * 2021-12-31 2025-08-28 Hitgen Inc. Menin inhibitor and use thereof
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
CN102186479A (zh) * 2008-09-10 2011-09-14 凯利普西斯公司 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
SG177628A1 (en) * 2009-07-30 2012-03-29 Univ Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
JP5792171B2 (ja) * 2009-09-04 2015-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白血病を治療するための組成物および方法
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Also Published As

Publication number Publication date
EP2968342B1 (en) 2018-10-03
US9216993B2 (en) 2015-12-22
CA2904612A1 (en) 2014-10-09
JP2016512514A (ja) 2016-04-28
AU2014249233A1 (en) 2015-09-24
JP2018115214A (ja) 2018-07-26
US20160046647A1 (en) 2016-02-18
EP2968342A4 (en) 2016-07-27
KR20150130389A (ko) 2015-11-23
US20160137665A1 (en) 2016-05-19
US9505782B2 (en) 2016-11-29
US20140275070A1 (en) 2014-09-18
US20170253611A1 (en) 2017-09-07
WO2014164543A1 (en) 2014-10-09
US10160769B2 (en) 2018-12-25
JP6670885B2 (ja) 2020-03-25
EP2968342A1 (en) 2016-01-20
CN105188705A (zh) 2015-12-23
US9505781B2 (en) 2016-11-29
IL241193A0 (en) 2015-11-30
BR112015022602A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX2015011576A (es) Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos.
ZA202310395B (en) Substituted inhibitors of menin-mll and methods of use
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
HK1246593A1 (zh) 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
PH12018501955B1 (en) Bridged bicyclic inhibitors of menin-mll and methods of use
MY193249A (en) Anti-human cd19 antibodies with high affinity
IN2015DN00127A (es)
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
MX2015011617A (es) Xantinas sustituidas y metodos de uso de las mismas.
MX2016008448A (es) Conjugados de var2csa-farmaco.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
PH12016500643B1 (en) NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c'] DIPYRROL-2-YL
MX2016004945A (es) Procesos para la preparacion de compuestos plaguicidas.
MX392001B (es) Composiciones fertilizantes y métodos para hacer y utilizar las mismas.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
EP3888671A3 (en) Protein formulations
MX2015016603A (es) Composiciones de corticosteroides.
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
EA201892083A1 (ru) Замещенные ингибиторы менина-mll и способы применения
IES20140280A2 (en) Human targets II
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
UA78669U (en) 5,11-di(3,4-dimethylphenyl)-8-thioxo-13-(2-chlorophenyl)-3,5,7,11-tetraazatricyclo[7,3,1,02,7]tridec-2-ene-1,9-dicarbonitrile